Jade Biosciences (JBIO) Enterprise Value (2021 - 2026)

Jade Biosciences (JBIO) has 7 years of Enterprise Value data on file, last reported at -$311.3 million in Q1 2026.

• Quarterly Enterprise Value fell 308.47% year-over-year to -$311.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$311.3 million (down 308.47% YoY) and the FY2025 annual result came in at -$336.2 million, down 384.48% from the prior year.
• Enterprise Value climbed to -$311.3 million in Q1 2026, from -$336.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$59.6 million in Q2 2022 to a low of -$336.2 million in Q4 2025.
• A 5-year average of -$153.7 million and a median of -$129.2 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 56.45% — and 2025, when it sank 384.48%.
• Tracing JBIO's Enterprise Value over 5 years: stood at -$129.2 million in 2022, then climbed by 5.25% to -$122.4 million in 2023, then jumped by 43.33% to -$69.4 million in 2024, then slumped by 384.48% to -$336.2 million in 2025, then rose by 7.4% to -$311.3 million in 2026.
• The last three Enterprise Value figures came in at -$311.3 million (Q1 2026), -$336.2 million (Q4 2025), and -$198.9 million (Q3 2025), per Business Quant data.